TY - JOUR
T1 - Current Treatments for Anxiety and Obsessive-Compulsive Disorders
AU - Sayed, Sehrish
AU - Horn, Sarah R.
AU - Murrough, James W.
N1 - Funding Information:
Sehrish Sayed declares that she has no conflict of interest. Sarah R. Horn declares that she has no conflict of interest. In the past two years, Dr. Murrough has received research support from the National Institutes of Health, the National Institute of Mental Health, the Department of Veterans Affairs, the Doris Duke Charitable Foundation, the American Foundation for Suicide Prevention, the Brain and Behavior Research Foundation, Janssen Research and Development and Avanir Pharmaceuticals; he has served on advisory boards for Janssen Research and Development and Genentech and has provided consultation services for ProPhase, LLC and Impel Neuropharma. Dr. Murrough is named on a filed patent application for neuropeptide Y in the treatment of mood and anxiety disorders. Institutional conflict: Dr. Charney (Dean of Icahn School of Medicine at Mount Sinai), and Icahn School of Medicine at Mount Sinai have been named on use patents on ketamine for the treatment of depression and on ketamine for the treatment of PTSD. If ketamine were shown to be effective in the treatment of depression or PTSD, Dr. Charney and Icahn School of Medicine at Mount Sinai could benefit financially.
Publisher Copyright:
© 2014, Springer International Publishing AG.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Anxiety disorders are prevalent and represent an important focus of treatment within the field of psychiatry as well as within medicine more broadly. First-line pharmacotherapy treatment for anxiety disorders is serotonin selective reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). For patients who do not responsd to an initial first-line treatment, clinicians should ensure that there has been adequate exposure to the medication by assessing compliance and optimizing the prescribed dose. Non-response to a treatment trial should also prompt a re-evaluation of the diagnosis and a search for occult psychiatric, substance, or general medical disorders. Laboratory tests and other components of a diagnostic work-up should be considered if they have not already been completed. Following confirmation of the diagnosis, the clinician should consider a switch to an agent from a different class, for example a tricyclic antidepressant or monoamine oxidase inhibitor. Combination treatments with an antidepressant plus a benzodiazepine, second-generation antipsychotic, anticonvulsant, β-blocker, or other medication may be considered but data is limited. Psychotherapy is an important treatment component for anxiety disorders and should be implemented whenever feasible. Variants of cognitive behavioral therapy (CBT) in particular are effective in reducing anxiety symptoms, and data suggest that the combination for CBT plus medication may be particularly beneficial for patients. Obsessive-compulsive disorder (OCD), while sharing many clinical features with anxiety disorders, represents its own unique clinical challenge and has been removed from the category of anxiety disorders in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). SSRIs are first-line therapy for OCD and higher doses are often required compared with anxiety disorders or major depressive disorder. Exposure and response prevention may be a particularly helpful form of psychotherapy for this patient population. For severe, intractable OCD, deep brain stimulation may be an appropriate therapeutic option.
AB - Anxiety disorders are prevalent and represent an important focus of treatment within the field of psychiatry as well as within medicine more broadly. First-line pharmacotherapy treatment for anxiety disorders is serotonin selective reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). For patients who do not responsd to an initial first-line treatment, clinicians should ensure that there has been adequate exposure to the medication by assessing compliance and optimizing the prescribed dose. Non-response to a treatment trial should also prompt a re-evaluation of the diagnosis and a search for occult psychiatric, substance, or general medical disorders. Laboratory tests and other components of a diagnostic work-up should be considered if they have not already been completed. Following confirmation of the diagnosis, the clinician should consider a switch to an agent from a different class, for example a tricyclic antidepressant or monoamine oxidase inhibitor. Combination treatments with an antidepressant plus a benzodiazepine, second-generation antipsychotic, anticonvulsant, β-blocker, or other medication may be considered but data is limited. Psychotherapy is an important treatment component for anxiety disorders and should be implemented whenever feasible. Variants of cognitive behavioral therapy (CBT) in particular are effective in reducing anxiety symptoms, and data suggest that the combination for CBT plus medication may be particularly beneficial for patients. Obsessive-compulsive disorder (OCD), while sharing many clinical features with anxiety disorders, represents its own unique clinical challenge and has been removed from the category of anxiety disorders in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). SSRIs are first-line therapy for OCD and higher doses are often required compared with anxiety disorders or major depressive disorder. Exposure and response prevention may be a particularly helpful form of psychotherapy for this patient population. For severe, intractable OCD, deep brain stimulation may be an appropriate therapeutic option.
KW - Agoraphobia
KW - Anxiety
KW - Benzodiazepines (BZD)
KW - Beta-blockers
KW - Buspirone
KW - Cognitive behavioral therapy (CBT)
KW - D-cycloserine (DCS)
KW - Exposure and response prevention (ERP)
KW - Generalized anxiety disorder (GAD)
KW - Monoamine oxidase inhibitor (MAOI)
KW - Obsessive-compulsive disorder (OCD)
KW - Panic disorder (PD)
KW - Psychotherapy
KW - Serotonin norepinephrine reuptake inhibitors (SNRI)
KW - Serotonin selective reuptake inhibitors (SSRI)
KW - Social anxiety disorder (SAD)
KW - Specific phobia (SP)
KW - Tricyclic antidepressant (TCAs)
UR - http://www.scopus.com/inward/record.url?scp=85019332133&partnerID=8YFLogxK
U2 - 10.1007/s40501-014-0020-7
DO - 10.1007/s40501-014-0020-7
M3 - Review article
AN - SCOPUS:85019332133
SN - 2196-3061
VL - 1
SP - 248
EP - 262
JO - Current Treatment Options in Psychiatry
JF - Current Treatment Options in Psychiatry
IS - 3
ER -